TAILIEUCHUNG - báo cáo khoa học: " FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases | Pisani et al. Journal of Experimental Clinical Cancer Research 2011 30 16 http content 30 1 16 Journal of Experimental Clinical Cancer Research CASE REPORT Open Access FCR Fludarabine Cyclophosphamide Rituximab regimen followed by 90yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma a report of 9 cases 1 2 2 1 1 3 Francesco Pisani Carlo Ludovico Maini Rosa Sciuto Laura Dessanti Mariella D Andrea Daniela Assisi Maria Concetta Petti1 Abstract Background This retrospective analysis is focused on the efficacy and safety of radioimmunotherapy RIT with Zevalin in nine patients with recurrent follicular lymphoma FL who were treated in a consolidation setting after having achieved complete remission or partial remission with FCR. Methods The median age was 63 yrs range 46-77 all patients were relapsed with histologically confirmed CD20positive grade 1 or 2 FL at relapse they received FCR every 28 days F 25 mg m2x 3 days C 1 gr m2 day 1 and R 375 mg m2 day 4 for 4 cycles. Who achieved at least a partial remission with 25 bone marrow involvement was treated with 90Yttrium Ibritumomab Tiuxetan or MBq Kg up to a maximum dose 1184 MBq at 3 months after the completion of FCR. The patients underwent a further restaging at 12 weeks after 90Y-RIT with total body CT scan FDG-PET CT and bilateral bone marrow biopsy. Results Nine patients have completed the treatment FCR followed by 90Y-RIT 6 patients at MBq Kg 3 patients at MBq Kg . After FCR 7 patients obtained CR and 2 PR after 90Y-RIT two patients in PR converted to CR 12 weeks later. With median follow up of 34 months range 13-50 the current analysis has shown that overall survival OS is 89 at 2 years 76 at 3 years and 61 at 4 years. The most common grade 3 or 4 adverse events were hematologic one patient developed herpes zoster infection after 8 months following valacyclovir discontinuation another patient developed fungal infection. .

TỪ KHÓA LIÊN QUAN
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.